Cargando…
Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma
INTRODUCTION: The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant. CASE PRESENTATION: A 50‐year‐old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413201/ https://www.ncbi.nlm.nih.gov/pubmed/34497992 http://dx.doi.org/10.1002/iju5.12334 |
_version_ | 1783747611137671168 |
---|---|
author | Fukuta, Kyotaro Izaki, Hirofumi Shiozaki, Keito Nakanishi, Ryoichi Inai, Tohru Kataoka, Hideyuki Kudo, Eiji Kanda, Kazuya |
author_facet | Fukuta, Kyotaro Izaki, Hirofumi Shiozaki, Keito Nakanishi, Ryoichi Inai, Tohru Kataoka, Hideyuki Kudo, Eiji Kanda, Kazuya |
author_sort | Fukuta, Kyotaro |
collection | PubMed |
description | INTRODUCTION: The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant. CASE PRESENTATION: A 50‐year‐old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder cancer and acute renal failure were diagnosed. He was referred to our hospital and underwent radical cystectomy. Histological examination showed pathological stage T4aN2 nested variant of urothelial carcinoma. He received 3 cycles of gemcitabine and carboplatin adjuvant chemotherapy. However, para‐aortic lymph node metastasis appeared 7 months after cystectomy. He received pembrolizumab as systemic chemotherapy. After 10 cycles, the lesion remained undetectable and we evaluated the response as complete. He has received 18 cycles in total and no recurrences or metastases have been observed. CONCLUSION: Pembrolizumab may offer effective treatment for nested variant of urothelial carcinoma. |
format | Online Article Text |
id | pubmed-8413201 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84132012021-09-07 Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma Fukuta, Kyotaro Izaki, Hirofumi Shiozaki, Keito Nakanishi, Ryoichi Inai, Tohru Kataoka, Hideyuki Kudo, Eiji Kanda, Kazuya IJU Case Rep Case Reports INTRODUCTION: The nested variant of urothelial carcinoma is rare and shows poor prognosis. We report a case of complete response to pembrolizumab in recurrent nested variant. CASE PRESENTATION: A 50‐year‐old man visited another hospital with hematuria and weight loss. Clinical stage T4aN0M0 bladder cancer and acute renal failure were diagnosed. He was referred to our hospital and underwent radical cystectomy. Histological examination showed pathological stage T4aN2 nested variant of urothelial carcinoma. He received 3 cycles of gemcitabine and carboplatin adjuvant chemotherapy. However, para‐aortic lymph node metastasis appeared 7 months after cystectomy. He received pembrolizumab as systemic chemotherapy. After 10 cycles, the lesion remained undetectable and we evaluated the response as complete. He has received 18 cycles in total and no recurrences or metastases have been observed. CONCLUSION: Pembrolizumab may offer effective treatment for nested variant of urothelial carcinoma. John Wiley and Sons Inc. 2021-06-24 /pmc/articles/PMC8413201/ /pubmed/34497992 http://dx.doi.org/10.1002/iju5.12334 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Fukuta, Kyotaro Izaki, Hirofumi Shiozaki, Keito Nakanishi, Ryoichi Inai, Tohru Kataoka, Hideyuki Kudo, Eiji Kanda, Kazuya Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma |
title | Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma |
title_full | Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma |
title_fullStr | Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma |
title_full_unstemmed | Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma |
title_short | Complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma |
title_sort | complete response to pembrolizumab in recurrent nested variant of urothelial carcinoma |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413201/ https://www.ncbi.nlm.nih.gov/pubmed/34497992 http://dx.doi.org/10.1002/iju5.12334 |
work_keys_str_mv | AT fukutakyotaro completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma AT izakihirofumi completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma AT shiozakikeito completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma AT nakanishiryoichi completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma AT inaitohru completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma AT kataokahideyuki completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma AT kudoeiji completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma AT kandakazuya completeresponsetopembrolizumabinrecurrentnestedvariantofurothelialcarcinoma |